Literature DB >> 16944374

Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer.

Michael Pinkawa1, Bernd Gagel, Marc Dieter Piroth, Holger Borchers, Gerhard Jakse, Michael J Eble.   

Abstract

PURPOSE: To evaluate changes of dose distribution for both the prostate and the surrounding tissues after permanent brachytherapy as monotherapy for prostate cancer. PATIENTS AND METHODS: In 35 patients, CT scans were performed before, 1 day after (day 1) and 1 month after the implantation (day 30). Changes of prostate volume, dosimetric parameters, and distances between posterior prostate contour and rectal wall as well as prostate contour and prescription isodose were analyzed.
RESULTS: Prostate volume increased from 37+/-11 cm3 (mean+/-standard deviation) to 49+/-12 cm3 on day 1 and dropped to 40+/-9 cm3 on day 30. Prostate V100 increased from 87+/-7% to 90+/-7%, prostate D90 from 138+/-21 Gy to 151+/-30 Gy. Mean rectal volume covered by the prescription isodose rose from 0.4 cm3 to 1.0 cm3; a changing distance between the prostate and rectal wall was excluded as a reason. Prostate D90 (day 1) and rectum V100 (day 30) proved to be significantly higher for larger prostate sizes. The distance between the prescription isodose and the prostate contour increased particularly at the posterior and inferior borders: 1.9 mm and 2.5 mm on average (0.1 mm and -0.7 mm at opposite borders, respectively).
CONCLUSION: With a decreasing edema of the prostate, an increasing dose both to the prostate and the anterior rectal wall resulted--the postimplant interval is essential for the dosimetry report. Due to a larger edema, a higher prescription dose might be needed for optimal cancer control in smaller prostates. Compared to day 1, the dose to the surrounding tissues increased on day 30, particularly at the posterior and inferior prostate borders.

Entities:  

Mesh:

Year:  2006        PMID: 16944374     DOI: 10.1007/s00066-006-1529-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  9 in total

1.  Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds.

Authors:  Akitomo Sugawara; Jun Nakashima; Etsuo Kunieda; Hirohiko Nagata; Hirotaka Asakura; Mototsugu Oya; Naoyuki Shigematsu
Journal:  Radiat Oncol       Date:  2010-09-28       Impact factor: 3.481

2.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

3.  Radiation protection of persons living close to patients with radioactive implants.

Authors:  Theodor W Kaulich; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2010-01-28       Impact factor: 3.621

4.  Use of gold markers for setup in image-guided fractionated high-dose-rate brachytherapy as a monotherapy for prostate cancer.

Authors:  Pirus Ghadjar; Nicole Gwerder; Axel Madlung; Frank Behrensmeier; George N Thalmann; Roberto Mini; Daniel M Aebersold
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

5.  The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatment.

Authors:  Markus Karl Alfred Herrmann; Tammo Gsänger; Arne Strauss; Tereza Kertesz; Hendrik A Wolff; Hans Christiansen; Hilke Vorwerk; Clemens Friedrich Hess; Andrea Hille
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

6.  Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis.

Authors:  Michael Pinkawa; Marc D Piroth; Branka Asadpour; Bernd Gagel; Karin Fischedick; Jaroslav Siluschek; Mareike Kehl; Barbara Krenkel; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

7.  Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study.

Authors:  Markus K A Herrmann; Tereza Kertesz; Tammo Gsänger; Eugen Bloch; Gerhard Pollul; Mohamed Bouabdallaoui; Arne Strauss; Mareike Herrmann; Hans Christiansen; Hendrik A Wolff; Clemens F Hess; Andrea Hille
Journal:  Radiat Oncol       Date:  2012-02-20       Impact factor: 3.481

8.  A commentary on 125I seed brachytherapy for refractory loco-regional recurrence of non-anaplastic thyroid cancer.

Authors:  Yamei Wang; Haiyang Wang; Huawen Xia
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

9.  Case series analysis of post-brachytherapy prostate edema and its relevance to post-implant dosimetry. Post-implant prostate edema and dosimetry.

Authors:  Ajay Tejwani; Eva Bieniek; Lindsay Puckett; Amir Lavaf; Adel Guirguis; Aaron Bennish; Hani Ashamalla
Journal:  J Contemp Brachytherapy       Date:  2012-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.